- Home
- AVNT vs HCM Comparison
AVNT vs HCM Comparison
Compare AVNT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVNT | HCM |
|---|---|---|
| Founded | 1927 | 2000 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AVNT | HCM |
|---|---|---|
| Price | $43.14 | $15.19 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $46.33 | $13.75 |
| AVG Volume (30 Days) | ★ 975.8K | 28.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.81 | N/A |
| Revenue Next Year | $3.34 | $16.12 |
| P/E Ratio | $48.36 | ★ $5.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.48 | $11.51 |
| 52 Week High | $44.85 | $19.50 |
Technical Indicators
Market Signals| Indicator | AVNT | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 83.01 | 55.01 |
| Support Level | $38.30 | $14.58 |
| Resistance Level | $44.85 | $15.25 |
| Average True Range (ATR) | 1.37 | 0.39 |
| MACD | 0.42 | -0.04 |
| Stochastic Oscillator | 82.53 | 82.40 |
Price Performance
Historical ComparisonAbout AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.